HUMA Humacyte
- 5.465
- +0.185+3.50%
Humacyte News
Press Release: Humacyte Announces Pricing of $30.0 Million Registered Direct Offering
Humacyte Price Target Maintained With a $25.00/Share by EF Hutton
Humacyte Is Maintained at Buy by EF Hutton
Humacyte to Participate in a Conference Call With Benchmark
Analysts Conflicted on These Healthcare Names: Humacyte (HUMA) and Baxter International (BAX)
Humacyte, Inc. (HUMA) Increases Yet Falls Behind Market: What Investors Need to Know
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV) in Vascular Trauma Treatment on September 30, 2024
Humacyte Stock Falls on Plans to Sell up to $50M Shares to Lincoln Park
Express News | Humacyte: Co Has Right to Sell to Lincoln Park Shares of Co's Common Stock, Par Value $0.0001 per Share, Having Aggregate Value of up to $50Mln
Express News | Humacyte Inc: Co, Lincoln Park Capital Fund, LLC Entered Purchase Agreement and Registration Rights Agreement
Express News | Humacyte Option Alert: Oct 18 $7.5 Calls Sweep (30) Near The Ask: 1246 @ $0.201 Vs 4796 OI; Earnings 11/7 After Close [Est] Ref=$5.72
Humacyte Price Target Maintained With a $13.00/Share by Cantor Fitzgerald
Express News | Humacyte Announces Allowance of U.S. Patent Covering Biovascular Pancreas (Bvp™)
Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP)
EF Hutton Initiates Humacyte(HUMA.US) With Buy Rating, Announces Target Price $25
Benchmark Co. Remains a Buy on Humacyte (HUMA)
Humacyte to Participate at Upcoming Investor Conferences in September
Both Retail Investors Who Control a Good Portion of Humacyte, Inc. (NASDAQ:HUMA) Along With Institutions Must Be Dismayed After Last Week's 14% Decrease
Humacyte(HUMA.US) Officer Sells US$5.72 Million in Common Stock
Humacyte Reports Positive Results From ATEV Treatment of Vascular Trauma in Ukraine
Analysis
Price Target
No Data
No Data